5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines
ACS Chemical Neuroscience · 01.02.2023 · 14 (3) · 351-358
DOI: 10.1021/acschemneuro.2c00718 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, online erschienen am 11.01.2023. Verfasst von Lindsay P Cameron und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Graduate Program, University of California, Davis, Davis, California 95618, United States. Hauptthemen laut MEDLINE: Hallucinogens. Die Arbeit wurde bisher 133-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCRR NIH HHS, NIMH NIH HHS.
Abstract (Originalsprache)
Psychedelic compounds have displayed antidepressant potential in both humans and rodents. Despite their promise, psychedelics can induce undesired effects that pose safety concerns and limit their clinical scalability. The rational development of optimized psychedelic-related medicines will require a full mechanistic understanding of how these molecules produce therapeutic effects. While the hallucinogenic properties of psychedelics are generally attributed to activation of serotonin 2A receptors (5-HT2ARs), it is currently unclear if these receptors also mediate their antidepressant effects as several nonhallucinogenic analogues of psychedelics with antidepressant-like properties have been developed. Moreover, many psychedelics exhibit promiscuous pharmacology, making it challenging to identify their primary therapeutic target(s). Here, we use a combination of pharmacological and genetic tools to demonstrate that activation of 5-HT2A receptors is essential for tryptamine-based psychedelics to produce antidepressant-like effects in rodents. Our results suggest that psychedelic tryptamines can induce hallucinogenic and therapeutic effects through activation of the same receptor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroscience Graduate Program, University of California, Davis, Davis, California 95618, United States.
- Department of Chemistry, University of California, Davis, Davis, California 95616, United States.
- Institute for Psychedelics and Neurotherapeutics, University of California, Davis, Davis, California 95618, United States.
- Pharmacology and Toxicology Graduate Program, University of California, Davis, Davis, California 95616, United States.
- Center for Neuroscience, University of California, Davis, Davis, California 95618, United States.
- Department of Neurology, School of Medicine, University of California, Davis, Sacramento, California 95817, United States.
ORCID-Profile: John A Gray, David E Olson
Förderung
- NIGMS NIH HHS
- NCRR NIH HHS
- NIMH NIH HHS
- National Center for Research Resources
- University of California, Davis
- Camille and Henry Dreyfus Foundation
- National Institute of Mental Health
- National Institute of General Medical Sciences
Zitieren
APA
Cameron, L. P., Patel, S. D., Vargas, M. V., Barragan, E. V., Saeger, H. N., Warren, H. T., Chow, W. L., Gray, J. A., & Olson, D. E. (2023). 5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines. ACS Chemical Neuroscience, 14(3), 351-358. https://doi.org/10.1021/acschemneuro.2c00718
Vancouver
Cameron LP, Patel SD, Vargas MV, Barragan EV, Saeger HN, Warren HT, et al. 5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines. ACS Chemical Neuroscience. 2023;14(3):351-358. doi:10.1021/acschemneuro.2c00718
BibTeX
@article{Cameron2023,
author = {Cameron, Lindsay P and Patel, Seona D and Vargas, Maxemiliano V and Barragan, Eden V and Saeger, Hannah N and Warren, Hunter T and Chow, Winston L and Gray, John A and Olson, David E},
title = {5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines},
journal = {ACS Chemical Neuroscience},
year = {2023},
volume = {14},
number = {3},
pages = {351--358},
doi = {10.1021/acschemneuro.2c00718}
}
EUVIMED